SCHEMBL7015266

SCHEMBL7015266

COc1nc(OCCO)c(C#N)c(-c2ccccc2)c1C#N

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SQOR Q9Y6N5 9/20 0.55
ADORA1 P30542 4/20 0.49
MEN1 O00255 2/20 0.45
ALDH1A1 P00352 2/20 0.45
MAPT P10636 2/20 0.45
KMT2A Q03164 2/20 0.45
KDM4E B2RXH2 2/20 0.45
RXFP1 Q9HBX9 2/20 0.45
HPGD P15428 1/20 0.45
CASP1 P29466 1/20 0.45
CASP7 P55210 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
HSD17B10 Q99714 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
PIM1 P11309 3/20 0.45
NPC1 O15118 1/20 0.43
CRHBP P24387 1/20 0.43
RAB9A P51151 1/20 0.43
CRHR2 Q13324 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7016201 0.84 ADORA1 (0.68) ADORA1MEN1ALDH1A1MAPTKMT2A
SCHEMBL7022233 0.80 SQOR (0.57) SQORADORA1MEN1ALDH1A1MAPT
SCHEMBL7018055 0.80 SQOR (0.50) SQORADORA1MEN1ALDH1A1MAPT
SCHEMBL7020664 0.77 SQOR (0.56) SQORADORA1MEN1ALDH1A1MAPT
SCHEMBL7021847 0.77 SQOR (0.56) SQORADORA1MEN1ALDH1A1MAPT
SCHEMBL28383673 0.77 KDM4E (0.66) SQORADORA1MEN1ALDH1A1MAPT
SCHEMBL1421642 0.77 SQOR (0.56) SQORADORA1MEN1ALDH1A1MAPT
SCHEMBL1421834 0.77 KDM4E (0.62) ADORA1MEN1ALDH1A1MAPTKMT2A
SCHEMBL1422139 0.77 ADORA1 (0.47) SQORADORA1MEN1ALDH1A1MAPT
SCHEMBL1421727 0.77 PRF1 (0.51) SQORADORA1MEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030232860-A1 Medicine comprising dicyanopyridine derivative ASTELLAS PHARMA INC. (JP) 2003-12-18 US disclosed
EP-1302463-A1 MEDICINE COMPRISING DICYANOPYRIDINE DERIVATIVE YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2003-04-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232860-A1 Medicine comprising dicyanopyridine derivative KCNN3, KCNN2, KCNN1 SQOR 846/4885ADORA1 1628/4885MEN1 2381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.